276 related articles for article (PubMed ID: 30605855)
1. In silico drug design of inhibitor of nuclear factor kappa B kinase subunit beta inhibitors from 2-acylamino-3-aminothienopyridines based on quantitative structure-activity relationships and molecular docking.
Wang JL; Li L; Hu MB; Wu B; Fan WX; Peng W; Wei DN; Wu CJ
Comput Biol Chem; 2019 Feb; 78():297-305. PubMed ID: 30605855
[TBL] [Abstract][Full Text] [Related]
2. Optimization study towards more potent thiazolidine-2,4-dione IKK-β modulator: Synthesis, biological evaluation and in silico docking simulation.
Elkamhawy A; Youn Kim N; Hassan AHE; Park JE; Yang JE; Elsherbeny MH; Paik S; Oh KS; Lee BH; Lee MY; Shin KJ; Pae AN; Lee KT; Roh EJ
Bioorg Chem; 2019 Nov; 92():103261. PubMed ID: 31542718
[TBL] [Abstract][Full Text] [Related]
3.
Hammoudi NE; Benguerba Y; Attoui A; Hognon C; Lemaoui T; Sobhi W; Benaicha M; Badawi M; Monari A
J Biomol Struct Dyn; 2022 Feb; 40(2):886-902. PubMed ID: 32948119
[TBL] [Abstract][Full Text] [Related]
4. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel potent nuclear factor kappa-B inhibitors (IKK-β) via extensive ligand-based modeling and virtual screening.
Al-Sha'er MA; Almazari IS; Taha MO
J Mol Recognit; 2017 Jun; 30(6):. PubMed ID: 28008665
[TBL] [Abstract][Full Text] [Related]
6. 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase.
Aouidate A; Ghaleb A; Ghamali M; Ousaa A; Choukrad M; Sbai A; Bouachrine M; Lakhlifi T
Comput Biol Chem; 2018 Jun; 74():201-211. PubMed ID: 29635214
[TBL] [Abstract][Full Text] [Related]
7. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
8. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
10. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
Jiang MN; Zhou XP; Sun DR; Gao H; Zheng QC; Zhang HX; Liang D
J Biomol Struct Dyn; 2018 Nov; 36(14):3705-3717. PubMed ID: 29064324
[TBL] [Abstract][Full Text] [Related]
11. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
12. Design of Potential IKK-β Inhibitors using Molecular Docking and Molecular Dynamics Techniques for their Anti-cancer Potential.
Singh SP; Hussain I; Konwar BK; Deka RC; Singh CB
Curr Comput Aided Drug Des; 2021; 17(1):83-94. PubMed ID: 31899679
[TBL] [Abstract][Full Text] [Related]
13. In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.
Asadollahi-Baboli M
Mol Divers; 2016 Aug; 20(3):729-39. PubMed ID: 27209475
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
[TBL] [Abstract][Full Text] [Related]
15. Models for predicting IKKA and IKKB blockade.
Hu H; Snyder JP
J Chem Inf Model; 2012 Dec; 52(12):3190-9. PubMed ID: 23157456
[TBL] [Abstract][Full Text] [Related]
16. In Silico Exploration of 1,7-Diazacarbazole Analogs as Checkpoint Kinase 1 Inhibitors by Using 3D QSAR, Molecular Docking Study, and Molecular Dynamics Simulations.
Gao X; Han L; Ren Y
Molecules; 2016 May; 21(5):. PubMed ID: 27164065
[TBL] [Abstract][Full Text] [Related]
17. IKK-beta inhibitors: an analysis of drug-receptor interaction by using molecular docking and pharmacophore 3D-QSAR approaches.
Lauria A; Ippolito M; Fazzari M; Tutone M; Di Blasi F; Mingoia F; Almerico AM
J Mol Graph Model; 2010 Aug; 29(1):72-81. PubMed ID: 20537930
[TBL] [Abstract][Full Text] [Related]
18. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
[TBL] [Abstract][Full Text] [Related]
19. Development and design of novel cardiovascular therapeutics based on Rho kinase inhibition-In silico approach.
Ćirić Zdravković S; Pavlović M; Apostlović S; Koraćević G; Šalinger Martinović S; Stanojević D; Sokolović D; Veselinović AM
Comput Biol Chem; 2019 Apr; 79():55-62. PubMed ID: 30716601
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
